Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemo-Immunotherapy vs Concurrent Chemoradiotherapy in Unresectable Locally Advanced ESCC
NCT07559045Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Second Affiliated Hospital of Zunyi Medical University. Primary endpoints: Complete Response Rate and 1-Year Progression-Free Survival Rate. Started Jan 2026; status: recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07559045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559045.